| Open: | 0.64 | High: | 0.7395 | | Low: | 0.63 | Volume: | 2,670,500 | | Yield: | n/a | P/E Ratio: | n/a | | Bid: | 0.7141 | Ask: | 0.718 | | Ex Div. Date: | n/a | Ex Div. Amount: | n/a |
| Overview: |
CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; new cold fill manufacturing service to the pharmaceutical industry, and LEAPS technology, with two products: H1N1, a swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted. It is the cancer immunotherapy that both kills cancer cells and activates the general immune system to destroy the cancer.
More from Reuters »
|
| Contact: |
No information available. |
Spam Report:  |
8 possible spam reported.
Latest spam reported on 07-26-2004
[ view the detailed CVM spam report ] |
|
Subscribe to our newsletter to get free stock market tips and investment advice! (317 subscribers)
RSS Feed
XHTML
RSS